Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Darzalex (daratumumab)
i
Other names:
HuMax-CD38, Dara IV, JNJ-54767414
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(26)
News
Trials
Company:
Genmab, J&J
Drug class:
CD38 inhibitor
Related drugs:
‹
isatuximab-irfc (11)
daratumumab/hyaluronidase (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
isatuximab-irfc (11)
daratumumab/hyaluronidase (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
›
Associations
(26)
News
Trials
Search handles
@Abdallah81MD
@GomezDLeonMD
@Myeloma_Doc
@PLMcCarthyMD
@Rfonsi1
@Transplant_Doc
@mtmdphd
Search handles
@Abdallah81MD
@GomezDLeonMD
@Myeloma_Doc
@PLMcCarthyMD
@Rfonsi1
@Transplant_Doc
@mtmdphd
Filter by
Latest
8ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
8 months ago
lenalidomide • Darzalex (daratumumab)
9ms
Humoral immune reconstitution following daratumumab, carfilzomib, lenalidomide, & dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and MRD-response-adapted treatment cessation https://t.co/06j16E5v3f @End_myeloma @TMSchmidtMD #mmsm (@e_JHaem)
9 months ago
lenalidomide • Darzalex (daratumumab) • carfilzomib
9ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
9 months ago
lenalidomide • Darzalex (daratumumab)
9ms
Ciltaca-cel significantly improved PFS over SOC pomalidomide, bortezomib, & dexamethasone or daratumumab, pomalidomide, & dexamethasone in pts w/ lenalidomide-refractory MM who received 1 to 3 prior lines of therapy. @bhemato @MedicalCollege #mmsm https://t.co/Pav2681nn1 (@OncLive)
9 months ago
Clinical
|
lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide
9ms
Ciltaca-cel significantly improved PFS over SOC pomalidomide, bortezomib, & dexamethasone or daratumumab, pomalidomide, & dexamethasone in pts w/ lenalidomide-refractory MM who received 1 to 3 prior lines of therapy. @bhemato @MedicalCollege #mmsm https://t.co/CGAxsgJTiz (@OncLive)
9 months ago
Clinical
|
lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide
9ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
9 months ago
lenalidomide • Darzalex (daratumumab)
9ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
9 months ago
lenalidomide • Darzalex (daratumumab)
9ms
Initial myeloma therapy is a great example, DarzalexRVD is such a complex regimen to explain at first, we all use these conversation devices to convince ourselves we did a good job but the nurses later will say: “they have no idea what you said, all they heard was cancer” (@shycollie)
9 months ago
Darzalex (daratumumab)
9ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
9 months ago
lenalidomide • Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUkfVv Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
Predictive Markers of High-Grade or Serious Tx-Emergent Infections w/ Daratumumab-Based Regimens in NDMM - Van De Donk et al. #ASH20 Abs 3209 https://t.co/E2Jv6CixC7 #mmsm #IDonc The final (MVA) predictive model included age, LDH, albumin & elevated baseline ALT levels (Table) (@mtmdphd)
10 months ago
Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
#ASCO23 @DholariaMD et al presents phase 2 trial results for Talquetamab + daratumumab in patients with relapsed/refractory multiple #myeloma: Updated TRIMM-2 results @BldCancerDoc (@OncLive)
10 months ago
Clinical • P2 data
|
Darzalex (daratumumab) • Talvey (talquetamab-tgvs)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
Analysis of data among Black participants treated with a daratumumab-containing D-RVd regimen from the #GRIFFINStudy in #MultipleMyeloma by @AjayNookaMD and colleagues https://t.co/2GZhxEG57D (@Plainlang_FSG)
10 months ago
Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
Highlighting Progress in Myeloma Treatment: POLLUX Trial Final Overall Survival Results With Daratumumab-Based Therapy, by Shaji Kumar, MD https://t.co/hrloOxuPnO #mmsm #MultipleMyeloma #hematology @myelomaMD (@ASCOPost)
10 months ago
Clinical
|
Darzalex (daratumumab)
10ms
📣Our latest @TheIACH Journal Club: Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) Now available on-demand! 📽️View the full webinar for FREE https://t.co/rI1oBq60nF @thanosdimop @Mohty_EBMT (@TheIACH)
10 months ago
Clinical
|
lenalidomide • Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
📣Join us NOW! ⬇️⬇️⬇️ https://t.co/y9wgvPS088 Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) ✍️FREE registration! @thanosdimop @Mohty_EBMT (@TheIACH)
10 months ago
Clinical
|
lenalidomide • Darzalex (daratumumab)
10ms
📣Join us TOMORROW for @TheIACH Journal Club: Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) FREE registration⬇️ https://t.co/7tD8XQnQ2F Tuesday, May 23 2023 6pm Paris, 12pm NY @thanosdimop @Mohty_EBMT (@TheIACH)
10 months ago
Clinical
|
lenalidomide • Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
11ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
11 months ago
lenalidomide • Darzalex (daratumumab)
11ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
11 months ago
lenalidomide • Darzalex (daratumumab)
12ms
In recent #HematologyNews, #daratumumab plus #lenalidomide and #dexamethasone treatment resulted in improved overall survival among patients with R/R #MultipleMyeloma. Learn more about Dr Dimopoulos' research here: https://t.co/tyW8FcRgOj @thanosdimop (@OncLearnNetwork)
12 months ago
Clinical
|
FCER1G (Fc Fragment Of IgE Receptor Ig)
|
lenalidomide • Darzalex (daratumumab)
1year
The addition of daratumumab to induction with VRd (Dara-VRd) did not lead to any clinically significant differences in stem cell yield and number of collection days, provided patient received pre-emptive GCSF and plerixafor #mmsm #bmtsm @hamzahashmi87 https://t.co/tbmvqx0f1q (@Transplant_Doc)
1 year ago
Clinical
|
Darzalex (daratumumab) • plerixafor
1year
Daratumumab mechanisms of resistance in myeloma: 1) Clone selection of CD38dim MM cells 2) CD38 reduction via CD38 endocytosis, trogocytosis by granulocytes & monocytes, & via release of CD38-expressing microvescicles that contribute to ADO production #mmsm #USMIRC #MedTwitter (@Abdallah81MD)
1 year ago
CD38 (CD38 Molecule)
|
CD38 expression
|
Darzalex (daratumumab)
almost2years
MyDRUG - @theMMRF & @myelomaMD https://t.co/8FzF2pPxUc https://t.co/ur8kCdvXsq #NCT03732703 #mmsm #PrecisionMedicine Initially, 6 arms w/ IPd + A1 CDK Abemaciclib B1 IDH2 Enasidenib C1 RAS/RAF Cobimetinib D1 FGFR3 Erdafitinib E1 t(11;14) Venetoclax Y1 N.A. Daratumumab (@mtmdphd)
almost 2 years ago
IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Darzalex (daratumumab) • Idhifa (enasidenib)
over2years
Fortunately Daratumumab works for CD20+ myeloma due to ubiquitous expression of CD38 by all subtypes of myeloma cells (@ChaulagainMD)
over 2 years ago
IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule)
|
CD38 expression
|
Darzalex (daratumumab)
over2years
#Myeloma Paper of the Day: Study of the efficacy and safety of #Darzalex + #ATRA in relapsed/refractory #myeloma finds ATRA transiently enhances CD38 expression but does not resensitize to #Darzalex, with response rate of only 4.5%: https://t.co/ObUXPrYHLf. (@Myeloma_Doc)
over 2 years ago
Clinical • IO biomarker
|
CD38 (CD38 Molecule)
|
CD38 expression
|
Darzalex (daratumumab)
over2years
Efficacy and Safety of Daratumumab w ATRA in RRMM.The combination has limited activity in daratumumab-refractory MM pts. The limited efficacy may be partially explained by the transient increase in CD38 expression upon ATRA treatment https://t.co/d0DbW7gIeI #mmsm #MedTwitter (@Abdallah81MD)
over 2 years ago
Clinical • IO biomarker
|
CD38 (CD38 Molecule)
|
CD38 expression
|
Darzalex (daratumumab)
over2years
Loss of CD38 expression in myelomatous pleural effusion in a patient with myeloma treated with daratumumab: Report of a case https://t.co/HX3npgY6ab #mmsm (@Rfonsi1)
over 2 years ago
Clinical • Pleural effusion • IO biomarker
|
CD38 (CD38 Molecule)
|
CD38 expression
|
Darzalex (daratumumab)
over2years
#Myeloma Paper of the Day: Pre-clinical data show that the BCMA-specific ADC MEDI2228 and #Darzalex induce synergistic #myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression: https://t.co/jAuK6Ms0HM. (@Myeloma_Doc)
over 2 years ago
IO biomarker
|
CD38 (CD38 Molecule)
|
CD38 expression
|
Darzalex (daratumumab) • MEDI2228
over2years
2/3 $ATNM Assets overview: Multiple shots on goal. Multiple Targets: 1) CD45 in Ph 3, Ph 1/2 Leukemia, Lymphoma and immune cells 2) CD38 AWE Technology Actinium-225 conjugated to daratumumab @abbvie AML MDS MM 3) CD 33 AML, ph 1/2 MDS ph 1 MM ph 1 @OrbiMed @MPMCapital (@ej23ny)
over 2 years ago
CD33 (CD33 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
Darzalex (daratumumab)
over2years
Recent pub from the lab showing that CD38:CIP (CD55 and CD59) ratio is a critical determinant of NKT Lymphoma response to Daratumumab. Strategies to improve this ratio will improve efficacy of Daratumumab. Tks to @SiokBian_Ng @adj_23 for support. https://t.co/mjv7uCUOPP (@chngwj)
over 2 years ago
Clinical
|
CD59 (CD59 Molecule)
|
Darzalex (daratumumab)
almost3years
In the B cell tube, #hematogones (CD19+/CD10+) appear kappa restricted, which is a daratumumab-induced artifact. Remember #daratumumab is a IgG-kappa monoclonal anti-CD38 antibody & hematogones have a ton of CD38 on their surface. 2/ #hemepath @VincentRK @Myeloma_Doc @mtmdphd (@sanamloghavi)
almost 3 years ago
CD19 (CD19 Molecule) • MME (Membrane Metalloendopeptidase)
|
Darzalex (daratumumab)
over3years
Until now, the only data available on anti-CD38 as a single-agent in relapsed AL #amyloidosis was with daratumumab. Retrospective and prospective trials summarized in the following table by @Terri_ParkerMD: #mmsm #ASH20 (@MM_Hub)
over 3 years ago
Retrospective data
|
CD38 (CD38 Molecule)
|
Darzalex (daratumumab)
over3years
MyDRUG - @theMMRF & @myelomaMD https://t.co/8FzF2pPxUc https://t.co/ur8kCdvXsq #NCT03732703 #mmsm #PrecisionMedicine Initially, 6 arms w/ IPd + A1 CDK Abemaciclib B1 IDH2 Enasidenib C1 RAS/RAF Cobimetinib D1 FGFR3 Erdafitinib E1 t(11;14) Venetoclax Y1 N.A. Daratumumab (@mtmdphd)
over 3 years ago
IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Darzalex (daratumumab) • Idhifa (enasidenib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login